Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer
Juan Liu, … , Wenwei Hu, Zhaohui Feng
Juan Liu, … , Wenwei Hu, Zhaohui Feng
Published February 7, 2023
Citation Information: J Clin Invest. 2023;133(6):e164354. https://doi.org/10.1172/JCI164354.
View: Text | PDF
Research Article Cell biology Oncology

The ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain of function in cancer

  • Text
  • PDF
Abstract

The tumor suppressor TP53 is the most frequently mutated gene in human cancers. Mutant p53 (mutp53) proteins often accumulate to very high levels in human cancers to promote cancer progression through the gain-of-function (GOF) mechanism. Currently, the mechanism underlying mutp53 accumulation and GOF is incompletely understood. Here, we identified TRIM21 as a critical E3 ubiquitin ligase of mutp53 by screening for specific mutp53-interacting proteins. TRIM21 directly interacted with mutp53 but not WT p53, resulting in ubiquitination and degradation of mutp53 to suppress mutp53 GOF in tumorigenesis. TRIM21 deficiency in cancer cells promoted mutp53 accumulation and GOF in tumorigenesis. Compared with p53R172H knockin mice, which displayed mutp53 accumulation specifically in tumors but not normal tissues, TRIM21 deletion in p53R172H knockin mice resulted in mutp53 accumulation in normal tissues, an earlier tumor onset, and a shortened life span of mice. Furthermore, TRIM21 was frequently downregulated in some human cancers, including colorectal and breast cancers, and low TRIM21 expression was associated with poor prognosis in patients with cancers carrying mutp53. Our results revealed a critical mechanism underlying mutp53 accumulation in cancers and also uncovered an important tumor-suppressive function of TRIM21 and its mechanism in cancers carrying mutp53.

Authors

Juan Liu, Cen Zhang, Dandan Xu, Tianliang Zhang, Chun-Yuan Chang, Jianming Wang, Jie Liu, Lanjing Zhang, Bruce G. Haffty, Wei-Xing Zong, Wenwei Hu, Zhaohui Feng

×

Figure 3

TRIM21 promotes mutp53 protein degradation through ubiquitination.

Options: View larger image (or click on image) Download as PowerPoint
TRIM21 promotes mutp53 protein degradation through ubiquitination.
(A) E...
(A) Ectopic expression of WT but not ΔRING TRIM21-Flag promoted the degradation of ectopic R175H and R273H mutp53 in p53−/− RKO cells, which was largely blocked by the proteasome inhibitor MG132. (B) MG132 treatment increased endogenous mutp53 protein levels and largely abolished the inhibitory effect of TRIM21-Flag on mutp53 protein levels in SK-BR3 and HT29 cells. (C) Ectopic expression of WT but not ΔRING TRIM21-Flag promoted ubiquitination of ectopic R175H and R273H mutp53 (but not wtp53) in p53−/− RKO cells analyzed by in vivo ubiquitination assays. Ub, ubiquitin. (D) TRIM21 KO reduced ubiquitination of endogenous R175H and R273H mutp53 in SK-BR3 and HT29 cells, respectively, analyzed by in vivo ubiquitination assays. (E) GST-TRIM21 protein ubiquitinated R175H and R273H His-mutp53 (but not His-wtp53) analyzed by in vitro ubiquitination assays using purified recombinant proteins. (F) Ectopic TRIM21-Flag expression decreased endogenous R175H mutp53 protein half-life in SK-BR3 cells. (G) TRIM21 KO increased endogenous R175H mutp53 protein half-life in SK-BR3 cells. In F and G, cells were treated with cyclohexamide (CHX) (50 μg/mL) for different amounts of time (hours) before Western blot assays. n = 3. (H) Ectopic TRIM21-Flag expression decreased mutp53 protein levels in both SK-BR3 and HT29 cells with or without MDM2 knockdown by 2 different shRNA vectors. (I) Ectopic expression of WT but not the ΔRING TRIM21-Flag decreased the levels of ectopic R175H mutp53 protein in both p53−/− and p53−/− MDM2−/− MEFs.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts